Phase 2 Pulmonary Hypertension Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older who have been diagnosed with HHT (Hereditary Haemorrhagic Telangiectasia) either through medical assessment or genetic testing
- People whose liver and kidneys are functioning at an adequate level
- (For Part B of the trial) People with HHT who experience nosebleeds and have low red blood cell levels, or who have a history of needing blood transfusions or iron treatment
- (For Part C of the trial) People with HHT who also have a confirmed diagnosis of a specific type of high blood pressure affecting the lungs (called pre-capillary pulmonary arterial hypertension)
Who may not be able to join:
- People who currently have an active infection or have had a serious infection recently
- People who have recently experienced a blood clot in a vein or artery (such as a deep vein thrombosis or stroke)
- People who have taken medications that work by blocking blood vessel growth within the past 6 weeks
- People who are currently pregnant or breastfeeding
- People who have recently taken part in another clinical research study involving an experimental treatment
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 339-233-4291
Australian sites
+61 (02) 9382 5800
+61 (02) 9382 5800
(03) 9970 4200
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
4 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part A (Single Dose); Incidence of Serious Adverse Events (SAEs) - Part A (Single Dose); Incidence of Dose-Limiting Toxicities (DLTs) - Part A (Single Dose); Number of participants with abnormal laboratory tests results - Part A (Single Dose); Number of participants with abnormal vital signs - Part A (Single Dose); Change from Baseline in Electrocardiogram (ECG) Parameters - Part A (Single Dose); Incidence of Treatment-Emergent Adverse Events (TEAEs) - Part B (Multiple Dose); Incidence of Serious Adverse Events (SAEs) - Part B (Multiple...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.